JOP20200286A1 - بنزاميدات مستبدلة بـ 1 ، 3-ثيازول-2-يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية - Google Patents
بنزاميدات مستبدلة بـ 1 ، 3-ثيازول-2-يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبيةInfo
- Publication number
- JOP20200286A1 JOP20200286A1 JOP/2020/0286A JOP20200286A JOP20200286A1 JO P20200286 A1 JOP20200286 A1 JO P20200286A1 JO P20200286 A JOP20200286 A JO P20200286A JO P20200286 A1 JOP20200286 A1 JO P20200286A1
- Authority
- JO
- Jordan
- Prior art keywords
- treatment
- thiazol
- diseases associated
- nerve fiber
- substituted benzamides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
يتعلق الاختراع الحالي باستخدام مركبات benzamide مستبدلة بـ 1,3-thiazol-2-yl من الصيغة العامة (I) كما وصفت وعرفت هنا، للتركيبات الصيدلانية والتوليفات التي تشتمل على المركبات المذكورة للمعالجة أو الوقاية من الأمراض المصاحبة لتحسس الألياف العصبية، وخاصة في العلاج والوقاية من السعال المزمن (CC) والتليف الرئوي مجهول السبب (IPF) واضطراب الانسداد الرئوي المزمن (COPD) والربو.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18172409 | 2018-05-15 | ||
PCT/EP2019/062332 WO2019219674A1 (en) | 2018-05-15 | 2019-05-14 | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20200286A1 true JOP20200286A1 (ar) | 2020-11-09 |
Family
ID=62186254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0286A JOP20200286A1 (ar) | 2018-05-15 | 2019-05-14 | بنزاميدات مستبدلة بـ 1 ، 3-ثيازول-2-يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210220358A1 (ar) |
EP (1) | EP3793554A1 (ar) |
JP (1) | JP2021523919A (ar) |
KR (1) | KR20210009341A (ar) |
CN (1) | CN112334132A (ar) |
AU (1) | AU2019269049A1 (ar) |
BR (1) | BR112020022553A2 (ar) |
CA (1) | CA3100099A1 (ar) |
CL (1) | CL2020002939A1 (ar) |
EA (1) | EA202092678A1 (ar) |
JO (1) | JOP20200286A1 (ar) |
MA (1) | MA52618A (ar) |
MX (1) | MX2020012202A (ar) |
SG (1) | SG11202011010YA (ar) |
TW (1) | TWI780329B (ar) |
WO (1) | WO2019219674A1 (ar) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10174016B2 (en) | 2014-12-09 | 2019-01-08 | Beyer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
AU2019353424B2 (en) | 2018-10-05 | 2022-12-08 | Shionogi & Co., Ltd. | Medicine for treating chronic cough |
EP3757103A1 (en) * | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
CN113082023B (zh) * | 2019-12-23 | 2024-03-01 | 武汉朗来科技发展有限公司 | P2x3抑制剂和p2x4抑制剂的药物组合及其应用 |
WO2021238834A1 (zh) * | 2020-05-25 | 2021-12-02 | 中国医药研究开发中心有限公司 | 芳甲酰胺类化合物及其制备方法和医药用途 |
JP2023543066A (ja) * | 2020-09-30 | 2023-10-12 | ヒューマンウェル ヘルスケア (グループ) カンパニー リミテッド | ベンザミド類化合物及びその使用 |
WO2022253943A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide |
WO2022253945A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
EP2262766B1 (en) * | 2008-02-29 | 2015-11-11 | Evotec AG | Amide compounds, compositions and uses thereof |
MX367657B (es) | 2013-08-23 | 2019-08-30 | Afferent Pharmaceuticals Inc | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. |
US10174016B2 (en) * | 2014-12-09 | 2019-01-08 | Beyer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
US10183937B2 (en) * | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
RS64155B1 (sr) * | 2015-09-29 | 2023-05-31 | Afferent Pharmaceuticals Inc | Diaminopirimidinski modulatori p2x3 i p2x2/3 receptora, za upotrebu u lečenju kašlja |
EA202092680A1 (ru) * | 2018-05-15 | 2021-04-13 | Байер Акциенгезельшафт | 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон |
-
2019
- 2019-05-14 KR KR1020207035583A patent/KR20210009341A/ko not_active Application Discontinuation
- 2019-05-14 US US17/055,488 patent/US20210220358A1/en not_active Abandoned
- 2019-05-14 AU AU2019269049A patent/AU2019269049A1/en active Pending
- 2019-05-14 EA EA202092678A patent/EA202092678A1/ru unknown
- 2019-05-14 MA MA052618A patent/MA52618A/fr unknown
- 2019-05-14 WO PCT/EP2019/062332 patent/WO2019219674A1/en unknown
- 2019-05-14 JP JP2020564269A patent/JP2021523919A/ja active Pending
- 2019-05-14 JO JOP/2020/0286A patent/JOP20200286A1/ar unknown
- 2019-05-14 TW TW108116606A patent/TWI780329B/zh active
- 2019-05-14 EP EP19723792.8A patent/EP3793554A1/en not_active Withdrawn
- 2019-05-14 MX MX2020012202A patent/MX2020012202A/es unknown
- 2019-05-14 SG SG11202011010YA patent/SG11202011010YA/en unknown
- 2019-05-14 BR BR112020022553-3A patent/BR112020022553A2/pt unknown
- 2019-05-14 CA CA3100099A patent/CA3100099A1/en active Pending
- 2019-05-14 CN CN201980042853.2A patent/CN112334132A/zh active Pending
-
2020
- 2020-11-12 CL CL2020002939A patent/CL2020002939A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202011010YA (en) | 2020-12-30 |
MA52618A (fr) | 2021-04-21 |
EP3793554A1 (en) | 2021-03-24 |
CL2020002939A1 (es) | 2021-03-05 |
CA3100099A1 (en) | 2019-11-21 |
KR20210009341A (ko) | 2021-01-26 |
MX2020012202A (es) | 2021-01-29 |
CN112334132A (zh) | 2021-02-05 |
TW201946924A (zh) | 2019-12-16 |
AU2019269049A1 (en) | 2020-11-26 |
TWI780329B (zh) | 2022-10-11 |
US20210220358A1 (en) | 2021-07-22 |
BR112020022553A2 (pt) | 2021-02-02 |
EA202092678A1 (ru) | 2021-04-12 |
JP2021523919A (ja) | 2021-09-09 |
WO2019219674A1 (en) | 2019-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200286A1 (ar) | بنزاميدات مستبدلة بـ 1 ، 3-ثيازول-2-يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية | |
MX2021014113A (es) | Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3). | |
EA201991793A1 (ru) | ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ | |
MX2019005526A (es) | Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa. | |
PH12018500088A1 (en) | Substituted tricyclics and method of use | |
JOP20150301B1 (ar) | بنزاميدات مستبدلة مع 3،1-ثيازول-2- يل | |
MX2017004950A (es) | Composiciones y metodos para tratar el insomnio. | |
BR112017009545A2 (pt) | composição antibacteriana, método para a preparação de uma composição, bacteriófago, ácido nucleico isolado, polipeptídeo isolado, e uso de um bacteriófago, ácido nucleico ou polipeptídeo | |
MX2019006495A (es) | Tratamiento de enfermedades neurologicas. | |
EA201891506A1 (ru) | Индолиноновые соединения и их применение в лечении фиброзных заболеваний | |
MX371178B (es) | Orvepitant para el tratamiento de la tos crónica. | |
PH12020500204A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease | |
MX2021014116A (es) | Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). | |
MX2021015553A (es) | Inhibidores de arginasa novedosos. | |
MX2023005801A (es) | Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3). | |
MX2023005803A (es) | Derivados de amino-quinazolina como inhibidores del purinorreceptor 3 p2x (p2x3). | |
EA202193300A1 (ru) | Производные аминохиназолина в качестве p2x3 ингибиторов | |
MX2023005805A (es) | Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3). | |
MX2019004366A (es) | Composiciones nebulizables de tiotropio y formoterol. | |
MX2023005865A (es) | Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. | |
MX2023005867A (es) | Derivados de dihidrofuropiridina como inhibidores de la cinasa rho. | |
MX2023005866A (es) | Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. | |
TR201716209A2 (tr) | Arformoterol ve umeklidinyum içeren yeni farmasötik bileşimler. | |
TR201716199A1 (tr) | Arformoterol ve ipratropium içeren yeni farmasötik bileşimler. | |
NZ761390A (en) | Boysenberry, apple, and blackcurrant compositions and methods of preparation and use therefor |